Chapter

Second- and third-line hormone therapies

Wolfgang Lilleby and Sophie Fosså

in Systemic Treatment of Prostate Cancer

Published on behalf of Oxford University Press

ISBN: 9780199561421
Published online May 2011 | e-ISBN: 9780199607372 | DOI: http://dx.doi.org/10.1093/med/9780199561421.003.0006

Series: Oxford Oncology Library

Second- and third-line hormone therapies

Show Summary Details

Preview

• Castration-refractory prostate cancer (CRPC) is defined as progression despite ongoing primary androgen deprivation therapy • Paradoxical androgen receptor stimulation can be seen and will respond to anti-androgen withdrawal • Steroids offer only limitedly-effective second-line therapy and one has to be aware of side effects • Selective blocking of cytochrome P17 with abiraterone opens a novel treatment option but is still an experimental approach.

Chapter.  1025 words.  Illustrated.

Subjects: Clinical Oncology

Full text: subscription required

How to subscribe Recommend to my Librarian

Buy this work at Oxford University Press »

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.